Transcode Therapeutics Inc (RNAZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Transcode Therapeutics Inc (RNAZ) has a cash flow conversion efficiency ratio of -34.445x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.98 Billion) by net assets ($144.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Transcode Therapeutics Inc for the company's overall valuation and market capitalisation.
Transcode Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Transcode Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Transcode Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Transcode Therapeutics Inc ranked by their cash flow conversion efficiency. Explore RNAZ operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Boardwalktech Software Corp
V:BWLK
|
-0.072x |
|
Dart Mining NL
AU:DTM
|
-0.035x |
|
QUHUO LTD SP.ADR/10 CL.A
F:9J40
|
N/A |
|
Northern Venture Trust
LSE:NVT
|
-0.025x |
|
Propell Holdings Ltd
AU:PHL
|
-0.056x |
|
ZAZZ Energy of Sweden AB
ST:ZAZZ-B
|
-0.063x |
|
Dotdigital Group Plc
LSE:DOTD
|
0.067x |
|
Camellia Plc
LSE:CAM
|
-0.059x |
Annual Cash Flow Conversion Efficiency for Transcode Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Transcode Therapeutics Inc from 2018 to 2025. View RNAZ stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $10.34 Million | $-19.52 Million | -1.888x | -128.58% |
| 2024-12-31 | $-2.02 Million | $-13.34 Million | 6.606x | +159.97% |
| 2023-12-31 | $1.64 Million | $-18.07 Million | -11.016x | -126.48% |
| 2022-12-31 | $3.24 Million | $-15.76 Million | -4.864x | -1784.33% |
| 2021-12-31 | $20.40 Million | $-5.27 Million | -0.258x | -278.46% |
| 2020-12-31 | $-3.41 Million | $-492.97K | 0.145x | -68.78% |
| 2019-12-31 | $-1.10 Million | $-508.51K | 0.463x | -22.05% |
| 2018-12-31 | $-503.97K | $-299.57K | 0.594x | -- |
About Transcode Therapeutics Inc
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastati… Read more